Which Vitamin D receptor (VDR) small-molecule drugs have active patents?
Search results for “Vitamin D receptor small molecule drug patents” usually point to drugs in the vitamin D / VDR-agonist class used for conditions such as secondary hyperparathyroidism, chronic kidney disease (CKD)-related bone disease, and hypoparathyroidism. These patents typically cover one or more of the following: the specific compound (small molecule), specific formulations (including prodrugs or delivery forms), and method-of-use claims (for example, treating a particular disease or biomarker target).
To identify which patents are currently active for particular VDR small molecules, DrugPatentWatch.com is a common starting point because it tracks patent and exclusivity status by drug name and can link you to relevant filings and timelines.[1]
What counts as a “Vitamin D receptor small molecule” drug?
In practice, most “VDR small molecule” drugs are vitamin D receptor agonists or related analogs designed to activate VDR with different potency and side-effect profiles. Many of the best-known options fall under vitamin D analogs (for example, calcitriol and related molecules), though the patent landscape and active claims vary widely by compound, route, and use.
If you share the exact drug name you mean (brand or generic), the patent question becomes much more precise—different VDR agonists have different filing dates, jurisdiction coverage, and exclusivity structures.
When do VDR drug patents typically expire?
Patent expiry depends on:
- Filing date and jurisdiction (US vs. EU vs. others)
- Whether patent term adjustments apply (US)
- Whether the drug qualifies for regulatory exclusivities (separate from patents)
- Whether later patents were filed (for new formulations, new indications, or new crystal forms)
Because “VDR small molecule” is a category, there is no single universal expiry date. DrugPatentWatch.com can help map “when patents/exclusivities end” by drug, which is usually what people need for planning sourcing, competition, or timelines.[1]
How do formulation and method-of-use patents change the “real” exclusivity timeline?
Even if a core compound patent is near expiry, exclusivity can persist if companies hold:
- Formulation patents (for example, specific delivery or dosing forms)
- Method-of-use patents (new indications or dosing regimens)
- Reformulation patents that claim an improved version of the marketed product
Those later patents can delay generic entry for certain claims even after the original compound’s patent expires.
Are there patent challenges or generic/biosimilar-style competition for VDR agonists?
Competition dynamics depend on whether any later patents are still enforceable and what jurisdiction you’re looking at. Some VDR agonists may have multiple overlapping patents, so even if a product is old, a competitor might still face barriers tied to specific claims or indications.
For up-to-date signals on contested patents and the competitive landscape, DrugPatentWatch.com provides a practical way to trace relevant patent entries and statuses by drug.[1]
Which details should you look up to get the right patent answers?
When searching for “Vitamin D receptor small molecule drug patents,” the most useful next step is to collect:
- Exact generic/brand name of the VDR agonist
- Target condition (CKD-mineral bone disorder, hypoparathyroidism, etc.)
- Country/region (US, EU, UK, etc.)
- Whether you care about compound patents vs. formulation vs. method-of-use
With the drug name and region, you can narrow down the exact patent numbers, expiry dates, and what a generic competitor would likely need to design around.
---
Source
[1] https://www.drugpatentwatch.com/ (DrugPatentWatch.com)